David Lloyd

David Lloyd is the current Vice President of Metabolic Disease at insitro. Prior to this, they served as the Senior Director of Pharmacology and Translational Biology at Carmot Therapeutics, Inc. from January 2021 to August 2022. Lloyd has also held the position of Scientific Director at Amgen from December 2005 to January 2021. David began their career as a Postdoctoral Fellow at GNF from October 2002 to December 2005, where they conducted forward genetics screening of metabolic disease mouse models and disease mechanisms.

David Lloyd earned a Doctor of Philosophy (Ph.D.) in Human/Medical Genetics from the University of Leicester. David also holds a Bachelor's Degree in Genetics from the University of Birmingham.

They work with Ajamete Kaykas - Chief eXploration Officer & Head of Neuroscience, Keith James - SVP, Drug Discovery, and Eric Mckeeby - Director of Communications. David Lloyd reports to Daphne Koller, Founder & CEO, Board Member.